Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions
This article was originally published in The Tan Sheet
Acquisitions and new products helped Perrigo grow quarterly revenue 23% to $718 million, despite manufacturing restraints related to an FDA warning letter.
You may also be interested in...
Perrigo stokes momentum behind already healthy sales growth with significant steps in separate areas: a green light for regulatory compliance at its main manufacturing plant, and the launch of its generic OTC versions of Sanofi-Aventis' Allegra.
In a year-and-a-half of heading Prestige Brands Holdings, Matthew Mannelly has been a change agent for the consumer health products firm.
Perrigo prioritized correcting manufacturing problems that drew an FDA warning, advising the firm to prevent human errors with tighter quality control, according to CEO Joseph Papa